Protocol Specific Research Support

$38,950P30FY2009CANIH

University Of Iowa, Iowa City IA

Investigators

Linked publications & trials

Paper 39689273 Paper 39678499 Paper 39606473 Paper 39484259 Paper 39471817 Paper 39463996 Paper 39422319 Paper 39393934 Paper 39379789 Paper 39373537 Paper 39369679 Paper 39369582 Paper 39362232 Paper 39349016 Paper 39348280 Paper 39347707 Paper 39345703 Paper 39343511 Paper 39343341 Paper 39337531 Paper 39333185 Paper 39330033 Paper 39329264 Paper 39321424 Paper 39314408 Paper 39302231 Paper 39302103 Paper 39298769 Paper 39297529 Paper 39293732 Paper 39287821 Paper 39287419 Paper 39282910 Paper 39265533 Paper 39259925 Paper 39258889 Paper 39258453 Paper 39257323 Paper 39256770 Paper 39255410 Paper 39248105 Paper 39241503 Paper 39241315 Paper 39233462 Paper 39233229 Paper 39225446 Paper 39222513 Paper 39218742 Paper 39213785 Paper 39213039 Paper 39201571 Paper 39201282 Paper 39195212 Paper 39189932 Paper 39182612 Paper 39179298 Paper 39169840 Paper 39169038 Paper 39168773 Paper 39167632 Paper 39167405 Paper 39154703 Paper 39122837 Paper 39117654 Paper 39116665 Paper 39106773 Paper 39104314 Paper 39104192 Paper 39098912 Paper 39090498 Paper 39083906 Paper 39067718 Paper 39062773 Paper 39061200 Paper 39058497 Paper 39054943 Paper 39054566 Paper 39054536 Paper 39048708 Paper 39044819 Paper 39043185 Paper 39042053 Paper 39025233 Paper 39013125 Paper 39003134 Paper 38996973 Paper 38994839 Paper 38987987 Paper 38976282 Paper 38973234 Paper 38969782 Paper 38943444 Paper 38935626 Paper 38933441 Paper 38932746 Paper 38926643 Paper 38925101 Paper 38914309 Paper 38911126 Paper 38904226

Abstract

As outlined throughout this proposal, the HCCC is currently involved in a number of phase I and other novel translational research trials that developed from laboratory work being done by HCCC investigators. These include not only therapeutic trials, but also trials of novel approaches to tumor imaging. The HCCC benefits from stable research staff to assist as outlined above with the conduct and completion of such innovative, short-term studies often performed by a team of investigators that has no prior clinical trial collaboration and hence no stable clinical trial support staff of their own. The availability of this resource during the prior funding period played a central role in the ability of the HCCC to strengthen its clinical and translational research activities. Evidence for this success in translational and clinical research is the successful competition for a lymphoma SPORE (P50CA097274), a "Molecular Imaging of Responses to Cancer Therapy" program grant (P20CA091709), and an AP4 planning grant focused on neuroendocrine and pediatric tumors (U56CA110083). Each of these programmatic clinical research initiatives now has separate funding, but was made possible by Protocol Specific Data Management support.

View original record on NIH RePORTER →